182 related articles for article (PubMed ID: 2700533)
1. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
Kraj M; Maj S; Pogłód R; Rostkowska J
Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
[TBL] [Abstract][Full Text] [Related]
2. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
4. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
Scudla V; Vavrdová V; Budíková M; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
[TBL] [Abstract][Full Text] [Related]
6. [Serum ferritin and beta-2-microglobulin in multiple myeloma].
Linkesch W; Ludwig H
Acta Med Austriaca; 1982; 9(5-6):227-31. PubMed ID: 6187172
[TBL] [Abstract][Full Text] [Related]
7. Serum ferritin and beta 2-microglobulin in patients with multiple myeloma.
Linkesch W; Ludwig H
Cancer Detect Prev; 1983; 6(1-2):297-301. PubMed ID: 6192921
[TBL] [Abstract][Full Text] [Related]
8. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.
Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
10. [The prognosis of patients with multiple myeloma--the aspect of histological distribution to the renal tissue and serum level of beta 2-MG].
Inoue Y; Suzuki K; Enomoto H; Takemura T; Nakamura K
Rinsho Ketsueki; 1992 Aug; 33(8):1012-6. PubMed ID: 1404855
[TBL] [Abstract][Full Text] [Related]
11. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
12. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
13. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
Iakovleva SV; Andreeva NE; Izgorodin AS
Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
[TBL] [Abstract][Full Text] [Related]
14. Type III procollagen N-peptide correlates with beta-2-microglobulin in myelomatosis.
Hasselbalch HC; Bjerrum OW; Junker P
Clin Lab Haematol; 1995 Sep; 17(3):237-41. PubMed ID: 8719897
[TBL] [Abstract][Full Text] [Related]
15. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
16. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
17. [beta2-Microglobulin and monoclonal gammapathies (author's transl)].
Belleville F; Bertrand F; Nabet P
Pathol Biol (Paris); 1978 Sep; 26(6):348-50. PubMed ID: 83581
[TBL] [Abstract][Full Text] [Related]
18. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma].
Abdulkadyrov KM; Stel'mashenko LV; Bessmel'tsev SS; Lubo-Lesnichenko IF; Sel'tser AV; Rozanova OE; Gubarenko NK; Bubnova LN; Mnuskina MM; Zhuchikhina AA; Blinov MN; Gritskevich NL
Vopr Onkol; 1998; 44(3):304-9. PubMed ID: 9695777
[TBL] [Abstract][Full Text] [Related]
20. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
